MoonLake shares rose 16% ahead of a key Investor day on Feb 23. Investors are seeking clarity on FDA feedback and regulatory strategy for Sonelokimab after a previous clinical setback. The stock dipped slightly in after-hours trading despite the recent gain. Analysts see a 7% upside from the current price.